- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05325346
A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
A Phase I, Open-Label, Randomized, Three-Period, Three-Sequence Crossover Study of the Effects of Co-administration of Intravenous VLX-1005 With Argatroban on Pharmacokinetics, Pharmacodynamics and Safety in Healthy Adult Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- Celerion, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy, adult, male or female (non-lactating and not of childbearing potential) subjects age 19 to 55 inclusive.
Females must have undergone one of the following sterilization procedures at least 6 months prior to the first dosing:
- hysteroscopic sterilization
- bilateral tubal ligation or bilateral salpingectomy
- hysterectomy
- bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year prior to the first dosing and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status.
- Good general health, with no significant medical history. Subjects must have no clinically significant abnormalities at screening, and/or before administration of the initial dose of study drug.
- Body weight ≥ 50 kg at the screening visit.
- Body Mass Index (BMI) between 18 and 32 kg/m2 inclusive.
- Laboratory values (clinical chemistry and hematology) within the normal reference range. Deviations from this range may be acceptable if they are considered 'not clinically significant' (NCS) by the PI, however, AST and ALT shall be <1.5x ULN. 7. Males who have not been vasectomized prior to participating in the study must agree to use at least 2 approved methods of contraception, or to abstain from sexual intercourse, from randomization until 90 days after their last dose of VLX-1005 and should refrain from donating sperm during that period. 8. Is a non-smoker and must not have used any nicotine products within three months prior to screening.
9. Able and willing to attend the necessary visits to the study center.
Exclusion Criteria:
- Blood donation or recipient of blood transfusion in previous 12 weeks.
- History of clinically significant endocrine, neurological, gastrointestinal, cardiovascular, hematological, hepatobiliary, immunological, renal, respiratory, or genitourinary abnormalities or diseases.
- History of neoplastic disease (with the exception of adequately treated nonmelanomatous skin carcinoma).
- Mentally or legally incapacitated (e.g. has significant emotional problems at the time of Screening Visit or expected during the conduct of the study, or has a history of a clinically significant psychiatric disorder within the last 5 years).
- Fever (body temperature >38 C) or symptomatic viral/bacterial infection or use of antibiotics within 2 weeks prior to Screening.
- Supine resting blood pressure (BP) >140/90 mmHg or heart rate (HR) >100 beats per minute at Screening and at Day -2.
- Clinically significant abnormality on ECG performed at the Screening Visit or prior to administration of the initial dose of study drug. (Abnormalities include not being in sinus rhythm, IVCD/BBB or QTcF>450 ms for males (470 ms for females)).
- Out of range (on repeat) testing for coagulation tests.
- Clinically significant laboratory abnormalities including: Impaired renal function (estimated creatinine clearance (CrCl) of <80 mL/minute based on CrCl = (140-age [years])(body weight [kg])/(72)(serum creatinine [mg/dL])).
- Positive test for hepatitis C antibody, hepatitis B surface antigen, or human immunodeficiency virus (HIV) antibody at Screening.
- Participants with a positive toxicology screening panel (urine test including qualitative identification of barbiturates, tetrahydrocannabinol, amphetamines, benzodiazepines, opiates, cocaine, cotinine and ethanol).
- Participants with a history of substance abuse or dependency or history of recreational IV drug use (by self-declaration).13. Participant has a suspected history of alcohol abuse in the 6 months prior to screening.
14. Use of NSAIDs, aspirin or aspirin-containing medications (and other medications affecting platelet function [for example cilostazol, clopidogrel, ticagrelor, prasugrel, dipyridamole]) in the 14 days prior to dosing with study medication. VerifyNow testing will be performed at check-in to exclude possible use of medications that affect platelet function.
15. Unable to refrain from or anticipates the use of any medications, including prescription and non-prescription drugs and herbal remedies (such as St. John's Wort [Hypericum perforatum]), beginning 14 days (or 5 half-lives, whichever is longer) before administration of the initial dose of study drug and continuing throughout the study until the final study visit. There may be certain medications that are permitted at the discretion of the PI and Sponsor (including paracetamol/acetaminophen, medications for the treatment of AEs following administration of study drug).
16. Subjects who are unlikely to comply with the study protocol or, in the opinion of the PI, would not be a suitable candidate for participation in the study.
17. Have participated in any other investigational drug trial within 30 days of dosing in the present study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VLX-1005
Intravenous administration of VLX-1005 with measurements of PK and PD
|
Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
|
Active Comparator: Argatroban
Intravenous administration of argatroban with measurements of PK and PD
|
Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
|
Other: VLX-1005 and Argatroban
Intravenous co-administration of VLX-1005 and argatroban with measurements of PK and PD
|
Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effects of argatroban on Cmax of VLX-1005
Time Frame: 0 - 51 hours
|
Measure the effects of argatroban on the maximum plasma concentration (Cmax) of VLX-1005
|
0 - 51 hours
|
Effects of VLX-1005 on Cmax of argatroban
Time Frame: 0 - 51 hours
|
Measure the effects of VLX-1005 on the maximum plasma concentration (Cmax) of argatroban
|
0 - 51 hours
|
Effects of argatroban on Tmax of VLX-1005
Time Frame: 0 - 51 hours
|
Measure the effects of argatroban on the time to maximum plasma concentration (Tmax) of VLX-1005
|
0 - 51 hours
|
Effects of VLX-1005 on Tmax of argatroban
Time Frame: 0 - 51 hours
|
Measure the effects of VLX-1005 on the time to maximum plasma concentration (Tmax) of argatroban
|
0 - 51 hours
|
Effects of argatroban on AUC(inf) of VLX-1005
Time Frame: 0 - 51 hours
|
Measure the effects of argatroban on the Area Under the Curve [AUC(inf)] of VLX-1005
|
0 - 51 hours
|
Effects of VLX-1005 on AUC(inf) of argatroban
Time Frame: 0 - 51 hours
|
Measure the effects of VLX-1005 on the Area Under the Curve [AUC(inf)] of argatroban
|
0 - 51 hours
|
Effects of VLX-1005 on whole blood aggregometry
Time Frame: 0 - 9 hours
|
The change in impedance from baseline by whole blood aggregometry will be measured to assess the effects of VLX-1005 on platelet aggregation
|
0 - 9 hours
|
Effects of argatroban on whole blood aggregometry
Time Frame: 0 - 9 hours
|
The change in impedance from baseline by whole blood aggregometry will be measured to assess the effects of argatroban on platelet aggregation
|
0 - 9 hours
|
Effects of VLX-1005 on PFA-100
Time Frame: 0 - 9 hours
|
Change in PFA-100 (a platelet pharmacodynamic measure) from baseline, to assess the effects of VLX-1005 on platelet aggregation
|
0 - 9 hours
|
Effects of argatroban on PFA-100
Time Frame: 0 - 9 hours
|
Change in PFA-100 (a platelet pharmacodynamic measure) from baseline, to assess the effects of argatroban on platelet aggregation
|
0 - 9 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as measured by incidence of Treatment Emergent Adverse Events
Time Frame: 0 - 30 days
|
To assess the effects on subject safety of VLX-1005 and argatroban alone and in combination as measured by incidence of Treatment Emergent Adverse Events as assessed by CTCAE, ver 5.0.
|
0 - 30 days
|
Effects of VLX-1005 on 12-HETE
Time Frame: 0 - 12 hours
|
12-hydroxyeicosatetraenoic acid (12-HETE), a platelet biomarker, will be measured to assess the effects of VLX-1005 on its production
|
0 - 12 hours
|
Effects of argatroban on 12-HETE
Time Frame: 0 - 12 hours
|
12-HETE, a platelet biomarker, will be measured to assess the effects of argatroban on its production
|
0 - 12 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Allen Hunt, MBA, Celerion
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VLX-1005-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heparin-induced Thrombocytopenia
-
Central Hospital, Nancy, FranceRecruitingHeparin-induced ThrombocytopeniaFrance
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingHeparin-induced Thrombocytopenia
-
University of ArizonaAmerican College of Clinical PharmacyRecruitingHeparin-induced ThrombocytopeniaUnited States
-
Aspen Global IncorporatedTerminatedHeparin-induced ThrombocytopeniaUnited States, Bosnia and Herzegovina, Canada, France, Germany, Italy, Poland, Russian Federation, Serbia
-
Marshall UniversityUnknownHeparin-induced ThrombocytopeniaUnited States
-
Ottawa Hospital Research InstituteUnknownHeparin-induced Thrombocytopenia (HIT)Canada
-
Vanderbilt University Medical CenterAmerican Heart AssociationCompletedHeparin-induced ThrombocytopeniaUnited States
-
Central Hospital, Nancy, FranceCompletedHeparin-induced Thrombocytopenia
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI)CompletedHeparin Induced ThrombocytopeniaUnited States
-
CHIR-NetUniversity Medicine GreifswaldCompletedLiver Transplantation | Heparin-induced ThrombocytopeniaGermany
Clinical Trials on VLX-1005
-
Veralox TherapeuticsCompletedSafety and Tolerability in Healthy VolunteersUnited States
-
Veralox TherapeuticsRecruitingHeparin Induced Thrombocytopenia | Thrombocytopenia, ImmuneUnited States
-
Staidson Biopharma Inc.Completed
-
Hunazine Biotech S.L.Recruiting
-
Staidson (Beijing) Biopharmaceuticals Co., LtdRecruiting
-
BioLite, Inc.CompletedMajor Depressive DisorderTaiwan, United States
-
Sound Pharmaceuticals, IncorporatedMedical University of South Carolina; Cystic Fibrosis FoundationEnrolling by invitation
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsUnited States
-
University of Alabama at BirminghamNational Cancer Institute (NCI)WithdrawnBreast Cancer | Gastric Cancer | Ovarian Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific
-
National Cancer Institute (NCI)WithdrawnBreast Cancer | Breast Neoplasms | Lung Neoplasms | Lung Cancer